Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

Cell - 21 Mar 2003

Azam Mohammad, Latek Robert R, Daley George Q

Abstract excerpt

The Bcr-Abl fusion protein kinase causes chronic myeloid leukemia and is targeted by the signal transduction inhibitor STI-571/Gleevec/imatinib (STI-571). Sequencing of the BCR-ABL gene in patients who have relapsed after STI-571 chemotherapy has revealed a limited set of kinase domain mutations that mediate drug resistance. To obtain a more comprehensive survey of the amino acid substitutions that confer STI-571...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Enzyme Inhibitors
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Source

Identifiers

PMID: 12654249
DOI: 10.1016/s0092-8674(03)00190-9

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.PMID 12654249Read ↗

Overriding imatinib resistance with a novel ABL kinase inhibitor.Semantic proximity Read ↗

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationSemantic proximity Read ↗

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.Semantic proximity Read ↗

HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistanceSemantic proximity Read ↗

A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment.Semantic proximity Read ↗

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.Semantic proximity Read ↗

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loopSemantic proximity Read ↗

Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571Semantic proximity Read ↗

Treating imatinib-resistant leukemia: the next generation targeted therapies.Semantic proximity Read ↗

[Novel inhibitors of Bcr-Abl].Semantic proximity Read ↗

The BCR-ABL Story: Bench to Bedside and BackSemantic proximity Read ↗

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.